P rimary percutaneous coronary intervention (PCI) is an effective treatment for myocardial infarction with ST-segment elevation when it can be performed rapidly. 1 However, primary PCI is performed at less than 25% of acute care hospitals in the United States. 2, 3 Many patients with myocardial infarction with ST-segment elevation present to hospitals that do not have the capability of performing PCI and therefore cannot undergo PCI within the timelines recommended in the guidelines 4 ; instead, they receive fibrinolysis as the initial reperfusion therapy. Although the proportion of such patients has decreased in recent years, 27.6% of the patients in the National Registry of Myocardial Infarction received fibrinolytic therapy in 2006. 5 The advisability of transferring such patients to a PCI center immediately after fibrinolysis for routine early PCI remains unclear. Initial studies of this issue did not show a clinical benefit of routine early PCI after fibrinolysis. 6, 7 More recent studies, performed in the era of coronary stenting and contemporary pharmacotherapy, have been more encouraging but have not been adequately powered to definitively establish the safety and efficacy of this approach. [8] [9] [10] [11] We therefore performed a large, randomized trial to compare a strategy of routine transfer and PCI within 6 hours after fibrinolysis with a standard strategy of transfer and PCI only in cases in which fibrinolytic therapy has failed.
Me thods

Study Design
The details of the trial design have been published previously. 12, 13 The Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) was a randomized, nonblinded trial performed at 52 sites in three provinces (Ontario, Manitoba, and Quebec) in Canada. The protocol was designed by the authors and approved by the local institutional research ethics committees at all participating hospitals. Data collection, site management, and data analysis were carried out at the Canadian Heart Research Centre.
The study was sponsored by the Canadian Institutes of Health Research, Roche Canada, and Abbott Vascular Canada; the sponsors had no involvement in the study design, data analysis, or manuscript preparation. The authors vouch for the accuracy and completeness of the data and the analyses.
Study Population
Patients with myocardial infarction with ST-segment elevation who presented within 12 hours after the onset of symptoms to participating centers that did not have the capability of performing PCI and who were treated with tenecteplase were screened for eligibility. Participants were eligible for inclusion in the study either if they had ST-segment elevation of 2 mm or more in two anterior leads or if they had ST-segment elevation of 1 mm or more in two inferior leads and at least one of the following high-risk characteristics: systolic blood pressure of less than 100 mm Hg, heart rate of more than 100 bpm, Killip class II or III, ST-segment depression of 2 mm or more in the anterior leads, or ST-segment elevation of 1 mm or more in right-sided lead V 4 (V 4 R), which is indicative of right ventricular involvement. Key exclusion criteria included cardiogenic shock before randomization, PCI within the previous month, previous coronary-artery bypass surgery, and the availability of primary PCI with an anticipated doorto-balloon time of less than 60 minutes. All participants provided written informed consent.
Interventions
All patients received tenecteplase, aspirin, and unfractionated heparin or enoxaparin in the emergency department. The protocol was amended in April 2005 to strongly recommend concomitant treatment with clopidogrel at the time of fibrinolysis (at an initial dose of either 300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.
Patients were randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment. Randomization was performed by the coordinating center (or in the case of Manitoba, by a physician delegated by the coordinating center) and was stratified according to the referring site and the patient's age (older than 75 years of age vs. 75 years of age or younger). Patients who were assigned to the early-PCI group were then transferred urgently to a PCI cen-ter with the goal of performing coronary angiography and PCI of the infarct-related artery within 6 hours after fibrinolysis. PCI was performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50 to 70% with thrombus, ulceration, or spontaneous dissection) was present.
Among patients assigned to the standard-treatment group, 12-lead electrocardiography was repeated 60 to 90 minutes after randomization; patients with persistent ST-segment elevation (i.e., a decrease in ST-segment elevation of less than 50%) and chest pain or with hemodynamic instability were transferred to another hospital for rescue PCI. All other patients in the standard-treatment group remained at their presenting hospital for at least 24 hours. It was recommended that patients undergo cardiac catheterization within 2 weeks after randomization, an approach that is consistent with the standards of practice at participating sites.
Stents were implanted during PCI whenever technically possible, and the use of Multi-Link Vision and Multi-Link Mini Vision cobalt chromium bare-metal stents, provided free of charge by Abbott Vascular Canada, was encouraged. The protocol allowed for the use of glycoprotein IIb/ IIIa antagonists during PCI and for 12 hours (if abciximab was the agent used) or 18 hours (if eptifibatide was used) after PCI at the discretion of the interventional cardiologist.
End Points
The primary end point of the study was the combined incidence of death, reinfarction, recurrent ischemia, new or worsening heart failure, or cardiogenic shock at 30 days. Secondary end points included death or reinfarction at 6 months and the incidence of bleeding complications, classified with the use of both the Thrombolysis in Myocardial Infarction (TIMI) and the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) severity scales. 14, 15 During the first 18 hours after enrollment, reinfarction was diagnosed on the basis of recurrent ST-segment elevation and recurrent chest pain lasting at least 30 minutes. After 18 hours, the diagnosis of reinfarction required that there be an elevation in the MB fraction of creatine kinase to higher than the upper limit of the normal range (more than three times the upper limit of normal after PCI and more than five times the upper limit of normal after coronary-artery bypass surgery) or new Q waves. Recurrent ischemia was defined as chest pain lasting 5 minutes or longer associated with ST-segment or T-wave changes. New or worsening heart failure was defined as heart failure that required treatment 6 hours or more after enrollment and either pulmonary edema on a chest radiograph, rales, or a pulmonarycapillary wedge pressure greater than 18 mm Hg. A diagnosis of cardiogenic shock was made when the systolic blood pressure remained at less than 90 mm Hg without inotropic support or when inotropic support was required to maintain systolic blood pressure above 90 mm Hg and there was clinical evidence of hypoperfusion. All nonfatal components of the primary end point were adjudicated by a clinical events committee whose members were unaware of treatment-group assignments.
Statistical Analysis
Assuming an event rate for the primary end point of 21% with the standard-treatment strategy and a 5% loss to follow-up, we estimated that a sample size of 1200 patients would be needed for the study to have 80% power to show a relative risk reduction of 30% with the early-PCI strategy, at an alpha level of 0.05. However, in November 2007, the steering committee decided to stop enrollment at the end of December 2007 owing to slowing enrollment, lack of additional funding, and loss to follow-up that was lower than anticipated.
An interim safety analysis was performed by the data safety and monitoring committee on data from the first 536 patients, and the committee identified no safety concerns. No interim efficacy analysis was performed.
All comparisons between the two treatment groups are based on the intention-to-treat principle. All statistical tests were performed at a significance level of 0.05 (two-sided) and have not been adjusted for multiple testing. Categorical variables are summarized with the use of absolute frequencies and percentages, and numerical variables with the use of medians and interquartile ranges. Between-group comparisons of the baseline characteristics and of the pretreatment evaluations were made to assess the similarity of the two treatment groups. Categorical variables were compared with the use of the Pearson chi-square test (Fisher's exact test was applied if the number of observations per cell was fewer than five). After assessment of normality with the Kolmogorov-Smirnov test, nonparametric tests (Wilcoxon rank-sum tests) were performed for the comparison of numerical variables between the two treatment groups.
Between-group comparisons of the cumulative event rate at 30 days for the primary combined end point and its components were performed with the Pearson chi-square test or Fisher's exact test. The time to the primary combined end point was analyzed with the use of the Kaplan-Meier method. The cumulative rates of death and of death or reinfarction at 6 months were compared between the treatment groups with the use of the chi-square test. The time to these end points was analyzed with the use of the Kaplan-Meier meth- od. The incidence of bleeding complications during the index hospitalization, as assessed according to the TIMI and GUSTO classifications of bleeding severity, was compared with the use of the Pearson chi-square test or Fisher's exact test.
R esult s
Patients
From July 10, 2004 , through December 27, 2007 , 1059 patients were randomly assigned to the standard-treatment group (522 patients) or the early-PCI group (537 patients). Baseline characteristics were well balanced between the two groups except that there was a higher prevalence of previous stroke or transient ischemic attack in the early-PCI group than in the standard-treatment group and a higher prevalence of previous congestive heart failure in the standard-treatment group than in the early-PCI group (Table 1) .
Procedures
Cardiac catheterization was performed in 88.7% of the patients in the standard-treatment group at a median of 32.5 hours after randomization and in 98.5% of the patients in the early-PCI group at a median of 2.8 hours after randomization (Table  2 and Fig. 1 ). PCI was performed in 67.4% of the patients in the standard-treatment group at a median of 21.9 hours after randomization and in 84.9% of the patients in the early-PCI group at a median of 3.2 hours after randomization. Urgent catheterization was performed within 12 hours after fibrinolysis in 182 (34.9%) of the patients in the standard-treatment group (Fig. 1) . The indications for urgent catheterization among these patients included reinfarction (20 patients), cardiogenic shock (7), new or worsening heart failure (2), recurrent ischemia (3), and persistent chest pain, ST-segment elevation, or both (131). In the case of the remaining 19 patients, the in- * BP denotes blood pressure, PCI percutaneous coronary intervention, and V 4 R right-sided lead V 4 . † Data were calculated on the basis of 521 patients in the standard-treatment group and 536 in the early-PCI group. ‡ Data were calculated on the basis of 522 patients in the standard-treatment group and 536 in the early-PCI group. § Data were calculated on the basis of 521 patients in the standard-treatment group and 535 in the early-PCI group. ¶ To qualify for participation in the trial, patients presenting with inferior ST-segment elevation were required to have at least one of the following high-risk characteristics: systolic blood pressure less than 100 mm Hg, heart rate more than 100 bpm, Killip class II or III, ST-segment depression of 2 mm or more in the anterior leads, or ST-segment elevation of 1 mm or more in lead V 4 R. ‖ Data were calculated on the basis of 522 patients in the standard-treatment group and 535 in the early-PCI group. dication for urgent catheterization was not documented.
Stents were implanted in 98.3% of the patients who underwent PCI, and glycoprotein IIb/IIIa antagonists were administered in 82.5%. Aside from a higher rate of clopidogrel use in the early-PCI group, the use of evidence-based medical therapy was similar between the treatment groups.
Efficacy Outcomes
A follow-up evaluation at 30 days was completed for all patients in the standard-treatment group and all but one patient in the early-PCI group (99.9% overall). The clinical end points are shown in Table 3 . The primary end point occurred in 11.0% of the patients in the early-PCI group and in 17.2% of the patients in the standard-treatment group (relative risk with early PCI, 0.64; 95% confidence interval [CI] , 0.47 to 0.87; P = 0.004) (Fig. 2 ). There were also significantly lower rates in the early-PCI group than in the standard-treatment group of recurrent ischemia (0.2% vs. 2.1%) and new or worsening congestive heart failure (3.0% vs. 5.6%). Fewer episodes of reinfarction were seen with routine early PCI than with standard treatment (3.4% vs. 5.7%), but this trend was not significant. Information on death and reinfarction at 6 months was available for 1039 patients (98.1%). At 6 months, the rates of reinfarction and of death or reinfarction did not differ significantly between the two groups (Table 3 and Fig. 3 ).
Adverse Events
Complications requiring treatment developed during transfer in 3.0% of the patients in the standardtreatment group who were transferred to a PCI facility and in 2.4% of the patients in the early-PCI group (all of whom were transferred to a PCI facility). The most common complication was hypotension. The only death that occurred during transfer was of a patient in the standard-treatment group who was being transferred for rescue PCI. There were more mild bleeding events, as assessed according to the GUSTO criteria, with the early-PCI strategy than with the standard-treatment strategy (13.0% vs. 9.0%, P = 0.04) but there were no significant differences in the rates of major or minor bleeding as assessed according to the TIMI criteria, moderate or severe bleeding as assessed according to the GUSTO criteria, transfusions, or intracranial hemorrhage. There were more deaths and episodes of cardiogenic shock at 30 days and more deaths at 6 months with the early-PCI strategy than with the standard-treatment strategy; however, the rates did not differ significantly.
Discussion
In this trial, we compared a strategy of prompt interhospital transfer for early PCI after fibrinolysis with a standard strategy of transfer for PCI only in cases in which fibrinolytic therapy has failed among 1059 patients presenting with STelevation myocardial infarction who could not undergo timely primary PCI. The primary end point, a composite of death, reinfarction, recurrent ischemia, congestive heart failure, or cardiogenic shock at 30 days, occurred significantly less frequently with early PCI than with standard therapy. No significant differences in the rates of major bleeding or transfusion were seen.
Trials of early PCI after fibrinolysis that were performed in the time before stents were used did not show a clinical benefit of this strategy and showed higher rates of major bleeding complications. 16 In one trial, there was a trend to higher mortality with early PCI. 6 One explanation that was proposed for the lack of benefit was that there is a risk of reocclusion after standard balloon angioplasty. 17 The implantation of coronary stents and the use of glycoprotein IIb/IIIa antagonists and thienopyridines reduce the incidence of reocclusion after successful PCI. [18] [19] [20] It is also possible that higher rates of bleeding episodes with early PCI may have offset any benefit achieved with this intervention. Bleeding rates after PCI have been reduced with the use of smaller sheaths, earlier removal of sheaths, radial access, the administration of lower doses of anticoagulants, and the elimination of postprocedural heparin infusions. 21 The use of highly fibrin-specific fibrinolytic agents such as tenecteplase is associated with lower rates of noncerebral bleeding. 22 Furthermore, the rates of emergency coronary-artery bypass surgery after PCI have dropped dramatically since the use of coronary stents has become routine. 23 All these advances have made PCI safer and more effective when performed early after fibrinolysis.
Trials performed after widespread use of stents became routine have shown encouraging results for PCI performed early after fibrinolysis. [8] [9] [10] [24] [25] [26] Our results are consistent with those of smaller trials and meta-analyses of trials in which contemporary PCI techniques and pharmacotherapy were used. [8] [9] [10] 16, [24] [25] [26] [27] [28] Our findings are similar to those seen in the recent Combined Abciximab Reteplase Stent Study in Acute Myocardial Infarction trial (CARESS-in-AMI; ClinicalTrials.gov number, NCT00220571), in which a half-dose of reteplase combined with abciximab was used as the initial reperfusion therapy. 26 The results of that trial, together with those of our study, suggest that, in order to be effective, such strategies would probably require adequate antiplatelet ther- apy with either glycoprotein IIb/IIIa antagonists combined with reduced-dose fibrinolysis or clopid ogrel combined with full-dose fibrinolysis and the liberal use of glycoprotein IIb/IIIa antagonists during PCI. The strategy of PCI performed a few hours after fibrinolysis -which was evaluated in our trial -should be distinguished from the strategy of PCI performed immediately after fibrinolysis, an approach that has been termed facilitated PCI. 29 Clinical trials of facilitated PCI have shown increased rates of bleeding and no clinical benefit with that strategy as compared with primary PCI alone. 30, 31 Although the reasons for these disap- pointing findings remain speculative, it is possible that the time between fibrinolysis and PCI (median, 90 to 104 minutes) was too short in these trials, with the result that persistent fibrinolytic activity led to increased bleeding complications. The lack of adequate antiplatelet therapy in these trials may have also conferred a predisposition to thrombotic complications. Fibrinolysis is followed by increased platelet activation and aggregation, and stent implantation early after fibrinolysis without adequate antiplatelet therapy may be associated with increased rates of acute stent thrombosis. 32 However, if the delay between fibrinolysis and PCI is too long, patients are exposed to the risk of reinfarction and recurrent ischemia while they await PCI, and patients in whom reperfusion after fibrinolysis is not successful may not be able to undergo rescue PCI quickly enough to salvage myocardium. Therefore, the goal in our trial was to perform catheterization and PCI within 6 hours after fibrinolysis; the actual median interval from lysis to balloon inflation in our study was 3.9 hours (interquartile range, 3.1 to 4.9). Our trial enrolled patients only at centers that did not perform PCI; these patients could not undergo timely primary PCI and were therefore treated with fibrinolysis. The strategy of fibrinolysis followed by routine early PCI was not directly compared with the strategy of primary PCI in this trial. Current guidelines recommend primary PCI for patients who can undergo coronary intervention within 90 minutes after presentation. 4 This trial was not powered to detect differences in mortality. There were six more deaths in the early-PCI group than in the standard-treatment group at 30 days, and seven more in the early-PCI group than in the standard-treatment group at 6 months, but the rates did not differ significantly. However, since five of the patients in the early-PCI group who died were in Killip class IV before randomization (despite the fact that cardiogenic shock was an exclusion criterion), this difference may have been due to a chance occurrence that there were more patients with cardiogenic shock before enrollment in the early-PCI group than there were in the standard-treatment group. A recent meta-analysis of contemporary trials (not including TRANSFER-AMI) has shown that there are significantly lower mortality and reinfarction rates with routine early PCI after fibrinolysis The primary end point was the composite of death, reinfarction, worsening heart failure, or cardiogenic shock within 30 days. PCI denotes percutaneous coronary intervention.
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than with a more conservative ischemia-guided approach. 27 Our trial was also underpowered to detect differences in the other individual components of the primary end point. It could be argued that a reduction in the rate of recurrent ischemia alone does not necessarily justify the strategy of routine early PCI after successful fibrinolysis, since pre- sumably a patient can be transferred for elective or urgent PCI if ischemia recurs. The benefit of routine early PCI with respect to new or worsening heart failure must be considered to be of uncertain significance, since new or worsening heart failure is only one of several secondary end points evaluated. The trend toward a reduction in the rate of reinfarction with routine early PCI was not significant. An alternative to the approach used in this trial would be a strategy of prompt transfer to a PCI center after fibrinolysis, followed by the selective use of PCI for only those patients with failed reperfusion or subsequent ischemic complications. This strategy, which might be designated "transfer and wait," was not studied in our trial. In our trial, nearly a third of the patients in the standardtherapy group underwent urgent catheterization within 12 hours after fibrinolysis, suggesting that a substantial number of patients for whom a transfer-and-wait strategy would be adopted (at least patients with a similar risk profile to that of our trial population) would require intervention.
In conclusion, among patients presenting with a myocardial infarction with ST-segment elevation who could not undergo timely primary PCI, we compared a strategy of prompt interhospital transfer for early PCI after fibrinolysis with a standard strategy of transfer for PCI only when fibrinolysis fails. The primary end point, a composite of death, reinfarction, recurrent ischemia, congestive heart failure, or cardiogenic shock at 30 days, occurred significantly less frequently with the early-PCI strategy than with standard therapy.
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